BernsteinKEOngFSBlackwellWL. A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev2013; 65: 1–46.
2.
WeiLClauserEAlhenc-GelasF. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem1992; 267: 13398–13405.
3.
O’NeillHGRedelinghuysPSchwagerSL. The role of glycosylation and domain interactions in the thermal stability of human angiotensin-converting enzyme. Biol Chem2008; 389: 1153–1161.
4.
DouglasRGEhlersMRSturrockEDThe anti-fibrotic peptide Ac-Sdkp: Opportunities for ACE inhibitor design. Clin Exp Pharmacol Physiol. Epub ahead of print 27 January 2013. DOI: 10.1111/1440-1681.12062.
5.
AziziMEzanERenyJL. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans. Hypertension1999; 33: 879–886.
6.
FuchsSXiaoHDColeJM. Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J Biol Chem2004; 279: 15946–15953.
7.
LangCCStruthersAD. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol2013; 10: 125–134.
8.
CampbellD. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Clin Exp Pharmacol Physiol1996; 3: S125–S131.
9.
NussbergerJBohlenderJ. Pharmacotherapy: Optimal blockade of the renin-angiotensin-aldosterone system. Nat Rev Cardiol2013; 10: 183–184.
10.
FuchsSXiaoHDHubertC. Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension2008; 51: 267–274.
11.
WoodmanZLSchwagerSLRedelinghuysP. The N domain of somatic angiotensin-converting enzyme negatively regulates ectodomain shedding and catalytic activity. Biochem J2005; 389: 739–744.
12.
JunotCGonzalesMFEzanE. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J Pharmacol Exp Ther2001; 297: 606–611.
13.
GeorgiadisDBeauFCzarnyB. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: Insights from selective inhibitors. Circ Res2003; 93: 148–154.
14.
van EschJHTomBDiveV. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. Hypertension2005; 45: 120–125.
15.
OcaranzaMPGodoyIJalilJE. Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension2006; 48: 572–578.
16.
WatermeyerJMKrogerWLO’NeillHG. Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril. Biochem J2010; 428: 67–74.
17.
DouglasRGEhlersMRESturrockED. Vasopeptidase inhibition: Solving the cardiovascular puzzle?Drugs Fut2011; 36: 33–43.
18.
JullienNMakritisAGeorgiadisD. Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem2009; 53: 208–220.
19.
GuJNoeAChandraP. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor−neprilysin inhibitor (ARNi). J Clin Pharmacol2010; 50: 401–414.
20.
RuilopeLMDukatABohmM. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study. Lancet2010; 375: 1255–1266.
21.
SolomonSDZileMPieskeB. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. Lancet2012; 380: 1387–1395.
22.
MaronBALeopoldJA. Aldosterone receptor antagonists: Effective but often forgotten. Circulation2010; 121: 934–939.
